Generic Name:
Cabozantinib
Project Status:
Withdrawn
Manufacturer:
Ipsen Biopharmaceuticals Canada Inc.
Brand Name:
TBD
Project Line:
Reimbursement Review
Project Number:
PC0123-000
Details
Tumour Type:
Genitourinary
Indications:
Renal Cell Carcinoma (RCC)
Funding Request:
For the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior therapy
Review Status:
Withdrawn
Pre Noc Submission:
Yes
Sponsor:
Ipsen Biopharmaceuticals Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
Clarification:
Ipsen Biopharmaceuticals Canada Inc. has notified pCODR that the Category 2 submission requirements for the pre NOC submission of Cabozantinib (Cabometyx) RCC cannot be met at this time. As per pCODR Procedures C3.1.6, the pCODR program has stopped the review.